Arkema (AKE) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
13 Jan, 2026Executive summary
Q2 2025 faced a challenging macroeconomic environment, with persistent weak demand in Europe and the US, but some growth in Asia and innovation-driven sectors like batteries and 3D printing.
EBITDA was €364 million, down 19.3% year-over-year, with a margin of 15.2%, reflecting resilience in high-performance polymers and adhesives but sharp declines in coatings and intermediates.
Adjusted net income was €118 million (€1.56/share), and recurring cash flow reached €111 million, both impacted by lower volumes and prices.
Cost-cutting and strict working capital management helped offset inflation and maintain robust cash generation, with cost-saving targets doubled to €100 million for 2025.
Major projects in innovative materials and key growth markets are ramping up, with new capacity coming online in the US, China, and Singapore.
Financial highlights
Q2 2025 revenue was €2,395 million, down 5.6% year-over-year, with a negative 3.3% currency effect and 1.3% volume decline.
EBITDA for the quarter was €364 million (down 19.3%), with a margin of 15.2%.
Adjusted net income was €118 million, or €1.56 per share, down 44.9% year-over-year.
Recurring cash flow reached €111 million; free cash flow was €91 million; working capital at 17% of annualized sales.
Net debt including hybrid bonds stood at €3,580 million at end of June 2025, with leverage at 2.5x LTM EBITDA.
Outlook and guidance
H2 2025 expected to continue with low demand, geopolitical uncertainty, and limited visibility on tariffs.
2025 EBITDA guidance set at €1.3–1.4 billion, including a €50 million FX headwind.
Recurring cash flow for 2025 expected between €300–400 million.
Cost savings target for 2025 raised to €100 million, double the previous annual target.
Over €400 million EBITDA contribution from major projects expected by 2028, assuming macro recovery.
Latest events from Arkema
- EBITDA dropped but cash flow and cost savings were strong, with Asia and growth markets outperforming.AKE
Q4 202526 Feb 2026 - Q2 2024 EBITDA rose 8.2% on 3.8% sales growth, with guidance raised for the year.AKE
Q2 20242 Feb 2026 - Q3 2024 EBITDA rose 5.4% to €407 million, margin at 17.0%, amid weak demand and tight debt control.AKE
Q3 202416 Jan 2026 - Ambitious growth, innovation, and sustainability drive strong specialty materials performance.AKE
BNPP Exane CEO Conference Presentation13 Jan 2026 - Q3 2024 saw higher sales and EBITDA, with strong specialty materials growth and sustainability focus.AKE
BOFA European Materials Conference 2024 Presentation13 Jan 2026 - Solid Q2 growth and sustainability focus drive higher 2024 EBITDA outlook of €1.53–1.63bn.AKE
Investor presentation13 Jan 2026 - Strong specialty materials growth, resilient margins, and major investments drive future expansion.AKE
Morgan Stanley Chemicals Cannonball Run Field Trip Presentation13 Jan 2026 - 2024 EBITDA rose 2.1% to €1.53bn, led by Specialty Materials and Asian growth.AKE
Q4 202418 Dec 2025 - Sales growth in Asia offset weak Western demand, but profits fell; 2025 outlook stable.AKE
Q1 202518 Nov 2025